PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today posted to the company website an overview of new, phase IIa data on the pharmacodynamics, safety, and pharmacokinetics of a small molecule antiviral in development for the treatment of HIV-1 infection – BMS-663068, an HIV-1 attachment inhibitor. The data were presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers SquibbMedia:Cristi Barnett, 609-252-6028cristi.barnett@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.com